BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,406.70
0.57%
S&P ASX All Technology
3,915.30
0.60%
Brent Oil
72.38
-0.10%
US Dollar vs AUD
1.54155
-0.19%
Bitcoin
93,182.48
1.32%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) News

Verastem Inc

Verastem Inc (VSTM)

NASDAQ
4.05
0.14
(3.58%)
Closed 27 November 8:00AM
Delayed by 15 minutes
4.05
0.00
( 0.00% )
Pre Market: 8:03PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

VSTM News

Official News Only

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
15 November 2024
VSTM (3.58%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
13 November 2024
VSTM (3.58%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
09 November 2024
VSTM (3.58%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 November 2024
VSTM (3.58%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 November 2024
VSTM (3.58%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
25 October 2024
VSTM (3.58%)

Form 8-K - Current report
Edgar (US Regulatory)
18 October 2024
VSTM (3.58%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
10 October 2024
VSTM (3.58%)

VSTM Discussion

View Posts
axelvento axelvento 1 month ago
stay tuned-----The oral presentation will include updated safety and efficacy data from the RAMP 201 trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC), including overall response rate, progression free survival, and duration of response.

Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT
👍️0
Monksdream Monksdream 3 months ago
VSTM under $3
👍️0
Monksdream Monksdream 4 months ago
VSTM new 52 week low
👍️0
Termite7 Termite7 6 months ago
https://www.verastem.com/research/pipeline/ Good pipeline!!!
👍️0
TheFinalCD TheFinalCD 6 months ago
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)

https://x.com/WallStDayTrader/status/1793988987092369420
https://x.com/Dogtor01416800/status/1793983764386939192
👍️ 1
TheFinalCD TheFinalCD 6 months ago
4.75 NOW VSTM over $18
👍️0
pmach64 pmach64 6 months ago
Brutal morning sell off after what appeared to be good news.
👍️0
tw0122 tw0122 6 months ago
VSTM over $18
👍️0
Monksdream Monksdream 7 months ago
VSTM over $10
👍️0
Harbor6460 Harbor6460 1 year ago
Read about it at 3.00 it looks like.
👍️0
muchogusto muchogusto 1 year ago
Worth reading
https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer
👍️0
Harbor6460 Harbor6460 1 year ago
It’s death after a RS. Wait for 4.00 or way under. Then Good risk reward
👍️0
muchogusto muchogusto 1 year ago
So, what is next for VSTM in terms of catalysts and results? Any upcoming data points? Is it now free from funding worries and free to focus on producing results? Tartia, your input would be appreciated.
👍️0
Harbor6460 Harbor6460 1 year ago
Happy I hit and run. I would consider this at under 4.00
👍️0
Harbor6460 Harbor6460 1 year ago
They definite are diluting. They need money. But in long run great for shareholder
👍️0
The Night Stalker The Night Stalker 2 years ago
highest volume in history -insert dd-
👍️0
Harbor6460 Harbor6460 2 years ago
Yep
👍️0
knrorrel knrorrel 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
oh my
👍️0
Triple nickle Triple nickle 2 years ago
Looks like dilution
👍️0
KeepOn KeepOn 2 years ago
Looks like real support at a dollar. Could be ready for next leg.
👍️0
Triple nickle Triple nickle 2 years ago
Added the dip
👍️0
Triple nickle Triple nickle 2 years ago
I post so others can ride with me to the victory circle so to speak.
I really like it when peeps get a good run.
👍️0
Invest-in-America Invest-in-America 2 years ago
VSTM: Well, Capt. T-N, you certainly scored MONSTER TIME on this one today, Dude!!! (EASY money for you, or WHAT, Bro!!! CONGRATS!!!)
👍️0
Harbor6460 Harbor6460 2 years ago
Halted?
👍️0
jchords jchords 2 years ago
Nice call
👍️0
Triple nickle Triple nickle 2 years ago
Okay nice run folks
👍️0
Triple nickle Triple nickle 2 years ago
.75 comin up

1.00 soon
👍️0
Triple nickle Triple nickle 2 years ago
LV2 still looks real thin
.75 ?
👍️0
Triple nickle Triple nickle 2 years ago
Really Good Friday here
👍️0
power11 power11 2 years ago
WHAT NEWS ??????
👍️0
Triple nickle Triple nickle 2 years ago
I’d be nice waking up to thirty bucks a share from this level
👍️0
shurtha2000 shurtha2000 2 years ago
This kind of news you can skip PHASEIII and go straight to approval
👍️0
Tartiaboy Tartiaboy 2 years ago
Next week it should run strong.
👍️0
Harbor6460 Harbor6460 2 years ago
This news is very positive
👍️0
Triple nickle Triple nickle 2 years ago
Peeps see double tops and think sell
Just bust through it
👍️0
Tartiaboy Tartiaboy 2 years ago
You would think.
👍️0
Triple nickle Triple nickle 2 years ago
Break past .52 come on
👍️0
Harbor6460 Harbor6460 2 years ago
Insiders are buying options. Time to load imo. Could see 2.00-3.00 like nothing
👍️0
SaltyOne SaltyOne 2 years ago
I'm with you on this one and so are the Baker Bros
👍️0
Harbor6460 Harbor6460 2 years ago
Never seen a board that nobody post wtf. Lol. We got things coming imo
👍️0
Harbor6460 Harbor6460 2 years ago
2 million volume yesterday. That’s a fund imo. I told you this was coming. Price of a stock does not reflect market value. This combo of drugs is a monster. I see 5-15.00 by Jan 2025
👍️0
Tartiaboy Tartiaboy 2 years ago
In addition to the progress with avutometinib + defactinib in LGSOC ONCT is moving two KRAS-G12C projects forward: avutometinib + sotorasib and avutometinib + adagrasib in KRAS-(G12C) NSCLC. Preclinical data suggests that we should see synergy with these combinations. I believe that the avuto + soto initial readout should happen at any time and this will be a big deal if the data is encouraging. In the preclinical data VSTM demonstrated that the synergistic effect of avutometinib + a G12C inhibitor was further enhanced with the addition of defactinib. I hope that they advance this G12C program with both the doublet and the triplet approach.

Clinical progress with the LGSOC program and the KRAS-G12C programs justify a much higher market cap than we have now. Any success with pancreatic cancer would be a total game-changer. The LGSOC and KRAS-G12C programs and low market cap provide a low risk opportunity to be in on the big prize which is Pancreatic cancer.
👍️0
Tartiaboy Tartiaboy 2 years ago
The RAMP201 and FRAME data for LGSOC is excellent so far. We should have final data readout in about 18 months (IMO). This data is expected to support an AA filing with the FDA for LGSOC. The current PPS does not reflect the significance of this. In addition, we have near term pending data on RAMP203 for RAS(G12C) NSCLC. Positive results with RAMP203 will further enhance value and help establish Avutometinib as a valid approach to RAS pathway cancers.

As an aside, I have my eyes on Akena's RAF:MEK clamp which may be even better than Avutometinib. The only problem is that Akena's molecule is several years behind Avuto in development.
👍️0
Tartiaboy Tartiaboy 2 years ago
I think that anyone interested needs to follow-up reading this PR by listening to the webcast presentation. It provides a more granular and encouraging overview than the PR alone does. I felt much more encouraged after hearing the overview and seeing the slides.

For instance the 28% ORR is interim data, not fully matured data. If one includes the 3 unconfirmed PRs the ORR is 38%. That's very good. If approved there will be TWO drugs approved.
👍️0
DrHarleyboy DrHarleyboy 2 years ago
Regulatory Update Following Type B FDA Meeting on LGSOC Program

A recent FDA meeting was held to discuss the encouraging results to date of the ongoing RAMP 201 trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirm the go forward treatment regimen selection and discuss the regulatory path forward. The combination of avutometinib with defactinib has been selected vs monotherapy as the go forward treatment in all recurrent LGSOC regardless of KRAS status, acknowledging the demonstrated contribution of defactinib.

The Company intends to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust to potentially support filing for accelerated approval. Both studies are evaluating avutometinib and defactinib in patients with recurrent LGSOC. The Company is in ongoing discussions with the FDA on the confirmatory study and plans to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study.

“We appreciate the productive and ongoing discussions with the FDA regarding the progress of our LGSOC program, including the alignment around key next steps as part of our breakthrough therapy designation,” said Brian Stuglik, CEO of Verastem Oncology. “With the encouraging results of the RAMP 201 Part A interim analysis and the FRAME study, we will work expeditiously to prepare to file for an accelerated approval that encompasses the totality of the data from both trials as well as progress on the confirmatory study.”

https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-data-and-regulatory-update
👍️0
Tartiaboy Tartiaboy 2 years ago
I already one a nice chunk. Listened to the webcast. Data looks very impressive. Open to discussing it.
👍️0
DrHarleyboy DrHarleyboy 2 years ago
Ramp 201 Data Updated, and a Private Placement secured.

BUY
👍️0
Harbor6460 Harbor6460 2 years ago
Looks like Big mews coming in next 3-6 months
👍️0
DrHarleyboy DrHarleyboy 2 years ago
Well, not time like the present to start a position, I doubt it can get much worse except go to $0.....

Still waiting on some results that will make or break this tiny Biotech.
👍️0

Your Recent History

NASDAQ
VSTM
Verastem
TSX
EPRX.WT.A
Eupraxia Pharmaceuticals
AQSE
ECP
Eight Capital Partners
USOTC
AERG
Applied Energetics (QB)
TSX
HWO
High Arctic Energy Servi...
EU
SGEEP
Euronext G Engie 030523 ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36